Will Stone
👤 SpeakerAppearances Over Time
Podcast Appearances
The study enrolled just over 80 current smokers who were randomly separated into two groups.
The other ingested a relatively high dose of pure psilocybin just one time.
At the six-month mark, the psilocybin group had more than six times greater odds of being abstinent from cigarettes than their counterparts who had nicotine.
Matthew Johnson at Johns Hopkins led the study.
Everyone in the trial also underwent 13 weeks of cognitive behavioral therapy.
Recent interest in psychedelics has mostly focused on depression and other mental health conditions.
Psilocybin could be considered for drug approval in the next few years.
The study enrolled just over 80 current smokers who were randomly separated into two groups.
The other ingested a relatively high dose of pure psilocybin just one time.
At the six-month mark, the psilocybin group had more than six times greater odds of being abstinent from cigarettes than their counterparts who had nicotine.
Matthew Johnson at Johns Hopkins led the study.
I was surprised by the sheer magnitude of the effect.
Everyone in the trial also underwent 13 weeks of cognitive behavioral therapy.
Recent interest in psychedelics has mostly focused on depression and other mental health conditions.
Psilocybin could be considered for drug approval in the next few years.
The editorial is titled Robert F. Kennedy Jr.